This technology presents a novel cancer diagnosis and treatment method using polydimethylsiloxane (PDMS) to enrich sub-populations of cells in melanoma.

About

Brief Description: This technology presents a novel cancer diagnosis and treatment method using polydimethylsiloxane (PDMS) to enrich sub-populations of cells in melanoma. It also introduces a new use of microbubbles formed in PDMS as a tool for determining the clonogenic potential (the ability of a single cancer stem cell to give rise to a clone) of tumor cells.   Applications: These assays could be used to enrich and identify cancer stem cells from cell lines, human primary tumors and metastatic tumors. Identification and recovery of these cells could lead to new diagnostic and therapeutic treatments for metastatic cancer. Furthermore, the technology can be used to enrich rare cells from a mixed population.   Advantages: These assays, in addition to being simple, cost effective, and rapid, provide humane alternatives to troublesome animal testing for determining the clonogenic potential of a mixed cell sample. This technology also provides a label-free method for identifying clones which have the ability to multiply easily. Most importantly, through the use of this technology and gene/protein expression profiling methods, new targeting models can be developed, providing a great opportunity for new cancer drugs to be discovered.  

Register for free for full unlimited access to all innovation profiles on LEO

  • Discover articles from some of the world’s brightest minds, or share your thoughts and add one yourself
  • Connect with like-minded individuals and forge valuable relationships and collaboration partners
  • Innovate together, promote your expertise, or showcase your innovations